AIM Vaccine Co., Ltd. (06660.HK) closed at HK$ 16.66, up 3.09%, on October 6, its first day on HKEx Main Board.

The data from the phase II clinical trial of mRNA (LVRNA009) targeting Covid-19 - independently developed by AIM Vaccine, have been known to the public. The live virus-neutralizing antibodies tested by Wuhan Institute of Virology, CAS, revealed that, the geometric mean titer (GMT) of the live virus-neutralizing antibodies 14 days after full-course vaccination of mRNA, was 994.9 in the adult medium-dose group and 1405.7 in the adult high-dose group. These figures prove mRNA is fairly strong in immunogenicity. Of note, the independent third-party tests indicate mRNA (LVRNA009) could fend off Omicron variants to a great extent.

Rong’an Bio, a wholly-owned subsidiary of AIM Vaccine, has submitted its application of communication session for the freeze-dried rabies vaccine for human use (serum-free Vero cell) it developed to the Center for Drug Evaluation (CDE), NMPA, thus entering the communication stage. As an upgrade, the serum-free Vero cell human rabies vaccine is most prominently characterized by serum-free cell culture, which results in higher safety.

A few days ago, AIM Convac, a subsidiary of AIM Vaccine Co., Ltd, submitted its application of communication session for the EV71-CA16 bivalent HFMD vaccine (human diploid cell) it developed to the Center for Drug Evaluation (CDE), NMPA, thus entering the communication stage. This candidate vaccine can target the two most common pathogens causing the hand-foot-and-mouth disease, i.e., enteric virus type 71 (EV71) and Coxsackie virus group A type 16 (CA16), to play an immunoprotective role in the comprehensive control and prevention of an HFMD epidemic.

Another success of AIM Vaccine Co., Ltd.—its wholly-owned subsidiary AIM Vacin obtained the Notice of Approval for Drug Clinical Trial for its ACYW135 Meningococcus Conjugate Vaccine (MCV4) from the National Medical Products Administration on December 1, and will carry out clinical trials in accordance with the requirements in the Notice.MCV4 is an industry-recognized international first-line innovative vaccine, and so far no similar product of its kind has obtained approval in China.

As declared by Zhejiang Provincial Department of Science and Technology on November 26, 2021, R&D of COVID-19 Vaccine Targeted at Delta Variant has been incorporated into Key “Pioneer” R&D Projects of Zhejiang Province for the year of 2022. This project is initiated by Ningbo Rong’an Biological Pharmaceutical Co., Ltd through cooperation with Zhejiang Provincial Center for Disease Control and Prevention. As the collaborator, Ningbo Rong’an Biological Pharmaceutical Co., Ltd is accelerating the development of inactivated COVID-19 vaccine targeted at Delta variant. So far, it has entered the non-clinical animal evaluation stage, including animal safety evaluation, immunogenicity evaluation and protection evaluation. In the near future, it will proceed with rolling submission of relevant information to Center for Drug Evaluation (CDE), NMPA.

Clinical test application for ACW135 meningococcal polysaccharide vaccine (MCV4) as independently developed by AIM Vaccine has been accepted by Center for Drug Evaluation, NMPA for approval. This indicates the initiation of formal approval of MCV4 for clinical tests.

Presently, there are only three foreign enterprises engaged in production of MCV4 worldwide, and no product has been approved for listing in China. AIM Vaccine comes into the frontier in China in terms of R&D of such key product.